Swiss IP office issues SPC clarification
Drazen_ / iStockphoto.com
Switzerland’s highest court held that new supplementary protection certificates (SPCs) for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, Teva, Mepha Pharma, SPC, Swiss Federal Supreme Court, Medeva, patent, harmonisation, CJEU, appeal, Truvada, HIV, AIDS